CureVac B.V. (CVAC) IPO Opens 175% Higher

Today's IPO for CureVac B.V. (NASDAQ: CVAC) opened for trading at $44 after pricing 13,333,333 common shares at an initial public offering price of $16.00.

In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions.

BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• BHP makes $38.8bn bid for Anglo American; analyst thinks improved offer is needed
• Loar Holdings (LOAR) Opens At $45, IPO At $28 (earlier)